Establishment of the MID‐NET ® medical information database network as a reliable and valuable database for drug safety assessments in Japan-Reference-Cited by-同舟云学术

Establishment of the MID‐NET ® medical information database network as a reliable and valuable database for drug safety assessments in Japan

Published:2019-08-29 Issue:10 Volume:28 Page:1395-1404
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Yamaguchi Mitsune¹,Inomata Satomi¹,Harada Sayoko¹,Matsuzaki Yu¹,Kawaguchi Maiko¹,Ujibe Mayuko¹,Kishiba Mari¹,Fujimura Yoshiaki²,Kimura Michio³,Murata Koichiro⁴,Nakashima Naoki⁵,Nakayama Masaharu⁶,Ohe Kazuhiko⁷,Orii Takao⁸,Sueoka Eizaburo⁹,Suzuki Takahiro¹⁰,Yokoi Hideto¹¹,Takahashi Fumitaka¹,Uyama Yoshiaki¹^ORCID

Affiliation:

1. Office of Medical Informatics and EpidemiologyPharmaceuticals and Medical Devices Agency Tokyo Japan

2. Head officeTokushukai Information System Incorporated Osaka Japan

3. Department of Medical InformaticsHamamatsu University Hospital Shizuoka Japan

4. Department of RadiologyKitasato University Hospital Kanagawa Japan

5. Department of Advanced Information TechnologyKyushu University Hospital Fukuoka Japan

6. Medical IT CenterTohoku University Hospital Sendai Japan

7. Department of Healthcare Information ManagementThe University of Tokyo Hospital Tokyo Japan

8. Department of PharmacyNTT Medical Center Tokyo Tokyo Japan

9. Department of Laboratory MedicineSaga University Hospital Saga Japan

10. Department of Medical InformaticsChiba University Hospital Chiba Japan

11. Department of Medical InformaticsKagawa University Hospital Kagawa Japan

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4879

Reference17 articles.

1. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan

2. Real-World Evidence — What Is It and What Can It Tell Us?

3. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

4. The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction;Platt R;Pharmacoepidemiol Drug Saf,2012

5. The FDA's sentinel initiative-A comprehensive approach to medical product surveillance

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness and caveats of real-world data for research on hypertension and its association with cardiovascular or renal disease in Japan;Hypertension Research;2024-09-11

2. PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage;Pharmacoepidemiology and Drug Safety;2024-09

3. Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET ^® in Japan;Journal of Dermatological Treatment;2024-07-04

4. Relationship of oral bacterial number with medical hospitalization costs in analysis of Diagnosis Procedure Combination database from single institution in Japan;Scientific Reports;2024-05-15

5. Detection Algorithms for Gastrointestinal Perforation Cases in the Medical Information Database Network (MID-NET®) in Japan;Therapeutic Innovation & Regulatory Science;2024-04-21